A grandmother, diagnosed with breast cancer, and her toddler granddaughter, diagnosed with acute myeloid leukemia, are facing ...

The Chehalis community will rally next week in a show of support for a W.F. West High School sophomore who was recently ...

The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and ...

Oct. 9, 2024 — Researchers have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions. The technology accurately ...

The FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older with relapsed/refractory acute leukemia and a lysine methyltransferase 2A gene ( ...

The sound of music is alive at georgetown high school.along with the chorus concert tonight - a special guest was recognized at the concert tonight for all that ...

Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.

All proceeds will benefit The Leukemia & Lymphoma Society’s efforts to support blood cancer patients and their families ...

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute ...

Danziten, a new formulation of nilotinib, may improve treatment adherence in patients with Philadelphia chromosome-positive ...

Findings of a recent study indicate that NUP98 rearrangements can significantly impact outcomes in patients with acute myeloid leukemia (AML).

The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase ...